The Dubai Ruler and Deputy Prime Minister sent similar cables of condolences to the Prime Minister of Italy, Giorgia Meloni
Chinese vaccine firm CanSino Biologic's inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac's shot, but the antibody level dropped in months, clinical trial data showed.
The result came as top political leaders in China called for proper tracking of virus mutation and developing of new vaccines and treatments in the country's effort to refine its Covid control strategy.
China has given about 56 per cent of its 1.41 billion population a booster dose using domestic shots, and most people were boosted with the same product as their primary series, despite growing evidence that some mix-and-max strategies would likely achieve higher antibody levels. read more
Among over 100 adults who received a lower dose of CanSinoBIO's (6185.HK) inhaled vaccine candidate following two Sinovac shots, after four weeks, 92.5 per cent developed the neutralising antibody that neutralises Omicron at levels that researchers defined as detectable, according to a paper published without peer review.
That compared with 88.9 per cent for a higher-dose group, also with over 100 participants, said in a paper published late on Thursday.
The rate for both groups declined to around 70 per cent after six months of the inhaled booster.
Barely any of the over 100 participants who received a third Sinovac shot had detectable neutralising antibody for Omicron after four weeks or six months.
The study did not compare CanSinoBIO's inhaled booster with other potential boosters that have triggered stronger antibody responses than a third dose of the Sinopharm or Sinovac shot.
Antibody-based readings reflect an important part of the vaccine-triggered immune response, and are different from the vaccine efficacy that indicates how well a shot reduces the risk of Covid disease, hospitalization or death.
The impact of BA.4 and BA.5 Omicron sub-variants on CanSinoBIO's inhaled vaccine deserves further study, said the authors, who worked at CanSinoBIO and other Chinese institutes.
CanSinoBIO's experimental inhaled vaccine uses a technology similar to that of its injection-based shot, which has been approved in countries including China, Mexico and Argentina, and AstraZeneca's vaccine.
The company is also testing a candidate based on the mRNA method in a mid-stage clinical trial in China.
ALSO READ:
The Dubai Ruler and Deputy Prime Minister sent similar cables of condolences to the Prime Minister of Italy, Giorgia Meloni
Abu Dhabi star underlines F2 dominance as battle for silver and bronze goes down to the wire
It is not immediately known how long the sailors were stranded in Yemen
Tight for second as Faysal Ayoubi and Charles Faulkner prevail on a countback
The Men in Green will kick off their campaign against The Netherlands on October 6 at the Rajiv Gandhi International Stadium in Hyderabad, India
Over 40 of Akasa's 450 pilots quit without serving their notice in recent weeks, causing 632 flight cancellations in August
He says migrants who risk drowning at sea 'must be rescued' because doing so was 'a duty of humanity'
In 16 ODIs this year, Babar scored 745 runs at an average of 49.66 and a strike rate of over 85